Thomson Scientific Expands Pharmaceutical Regulatory Intelligence Coverage

IDRAC® database now delivers regulatory intelligence from India, Israel and Turkey

Philadelphia, PA USA, London UK 12/21/2006
Thomson Scientific, part of The Thomson Corporation (NYSE: TOC; TSX: TOC) and leading provider of information solutions to the worldwide research and business communities, today announced that three new country modules — India, Israel and Turkey — are now available in IDRAC®, the global pharmaceutical regulatory intelligence database. These modules help meet the regulatory information needs of companies looking to accelerate their products’ entrance into the ever changing marketplace.

IDRAC is recognized by regulatory professionals the world over as the leading authority in global regulatory intelligence. Updated weekly, it brings together all the information needed to monitor regulatory requirements in 47 countries and regions, including these new additions:

• India: India is emerging as a preferred destination for pharmaceutical industry activities. The India module contains both regulatory and explanatory documents including consolidated versions of main acts and rules, comprehensive follow up of amendments to this legislation, plus the main regulatory guidelines and government policies.

• Israel: The Israeli pharmaceutical market is rapidly expanding. It is the home of leading generic companies, and pharmaceutical companies have also shown a growing interest in conducting clinical trials in Israel. The Israel module provides current or consolidated versions of the main texts ruling the pharmaceutical profession in Israel, plus the main guidelines as well as explanatory documents covering all regulatory aspects of drug development, registration and marketing.

• Turkey: Turkish legislation on the registration of medicinal products complies with the European Directive 2001/83/EC, and the Turkey module includes all relevant regulations. Explanatory Documents in the Turkey module cover Turkish legislation and main issues related to medicinal products registration, product information, clinical research, quality assurance, pharmacovigilance, advertising, pricing and reimbursement, and generics.

“The comprehensive drug regulatory information in IDRAC is designed to help pharmaceutical companies adapt to a constantly changing regulatory environment,” said Claude Basset, managing director of IDRAC, Thomson Scientific. “The recent emergence of India and Israel as hot spots for pharmaceutical activity are two examples of these changes, and we have introduced these new modules to ensure our customers are equipped with the latest regulatory intelligence when they make development decisions in these countries.”

Contact Information

Ryan Sheppard

Senior Director of Communications

Thomson Scientific & Healthcare

Contact via E-mail